LAURUS LABS LIMITED

The investor presentation for Laurus Labs Limited, dated September 2026, outlines the company's financial and operational performance, strategic initiatives, and future plans. The document highlights FY2026 revenue of ₹6,813 crore, a 23% year-over-year increase, with a CAGR of 16% from FY20 to FY26. EBITDA reached ₹1,826 crore, a 64% rise, with a margin of 26.8%, and management expects this margin to exceed 30% from FY27 onward. The company reported 8,470 employees and a net debt-to-EBITDA ratio of 1.3x. Key operational metrics include 15 manufacturing sites, 6 R&D centers, and over 1,570 scientists. Strategic focus areas include expanding CDMO capabilities, accelerating growth CAPEX projects, with management planning ₹3,000 crore over FY27 and FY28, and enhancing biotechnology platforms such as Gene Therapy and ADC. The presentation also details ESG initiatives, including SBTi targets for GHG reduction and a S&P Global ESG score of 81/100. Financial highlights for 1Q FY27 show revenue of ₹2,026 crore, a 29% YoY increase, with EBITDA of ₹644 crore and a margin of 31.8%. The company emphasized its integrated service model, diversified business segments, and long-term growth strategies across small molecules, biologics, and advanced therapies.

The document emphasizes strong financial performance, operational expansion, and strategic growth initiatives, reflecting a positive outlook.